Tarsus Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2017-01-01

Employees: 244

Market Cap: $1B

Website: http://tarsusrx.com

Introduction: Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Clinical Trials

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Phase 4

Recruiting

Conditions: Demodex Blepharitis

Interventions: Drug: Lotilaner ophthalmic solution, 0.25%
Drug: Vehicle control

First Posted Date: 2023-12-26

Last Posted Date: 2024-03-26

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 166

Registration Number: NCT06182358

Locations: 🇺🇸
Site, Houston, Texas, United States
🇺🇸
Vision Institute, Colorado Springs, Colorado, United States

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Phase 2

Active, not recruiting

Conditions: Meibomian Gland Dysfunction
Demodex Infestation of Eyelid
Blepharitis
Demodectic Blepharitis

Interventions: Drug: Vehicle of TP-03

First Posted Date: 2023-09-26

Last Posted Date: 2024-04-09

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT06054217

Locations: 🇺🇸
Shultz Chang Vision, Northridge, California, United States
🇺🇸
Vita Eye Clinic, Shelby, North Carolina, United States

Study of TP-04 in Participants With Papulopustular Rosacea

Phase 2

Completed

Conditions: Papulopustular Rosacea

Interventions: Other: Vehicle control gel
Drug: Lotilaner Gel, 2.0%

First Posted Date: 2023-05-01

Last Posted Date: 2023-11-24

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 37

Registration Number: NCT05838170

Locations: 🇨🇦
The Centre for Clinical Trials, Oakville, Ontario, Canada
🇨🇦
Innovaderm Research Inc., Montréal, Quebec, Canada
🇨🇦
SKiN Centre for Dermatology, Peterborough, Ontario, Canada

and more 2 locations

Study to Evaluate the Food Effect of TP-05 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TP-05 (lotilaner oral), fasted group
Drug: TP-05 (lotilaner oral), high-fat group
Drug: TP-05 (lotilaner oral), low-fat group

First Posted Date: 2023-02-09

Last Posted Date: 2023-06-28

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 42

Registration Number: NCT05720364

Locations: 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Phase 2

Completed

Conditions: Blepharitis
Demodex Infestation
Meibomian Gland Dysfunction

Interventions: Drug: TP-03
Drug: TP-03 Vehicle

First Posted Date: 2022-07-12

Last Posted Date: 2023-11-13

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT05454956

Locations: 🇺🇸
Medical Optometry America, New Freedom, Pennsylvania, United States
🇺🇸
Mitchell C. Shultz, MD, Northridge, California, United States
🇺🇸
Silverstein Eye Center, Kansas City, Missouri, United States

and more 2 locations

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

Phase 2

Active, not recruiting

Conditions: Healthy Volunteer

Interventions: Drug: Low Dose TP-05
Drug: High Dose TP-05
Drug: Placebo Comparator

First Posted Date: 2022-05-24

Last Posted Date: 2024-03-28

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT05387083

Locations: 🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States

A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TP-03 (Lotilaner Ophthalmic Solution), 0.25%

First Posted Date: 2021-12-01

Last Posted Date: 2024-04-12

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT05138861

Locations: 🇨🇦
Altasciences, Mount Royal, Quebec, Canada

A Pharmacokinetic Study of TP-05 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: TP-05 (lotilaner oral capsules)

First Posted Date: 2021-12-01

Last Posted Date: 2022-08-03

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 67

Registration Number: NCT05138796

Locations: 🇺🇸
Altasciences, Overland Park, Kansas, United States

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Phase 3

Completed

Conditions: Blepharitis

Interventions: Drug: TP-03
Drug: TP-03 Vehicle

First Posted Date: 2021-03-05

Last Posted Date: 2023-12-21

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 412

Registration Number: NCT04784091

Locations: 🇺🇸
Shultz Chang Vision, Northridge, California, United States
🇺🇸
Pankratz Eye Institute, Columbus, Indiana, United States
🇺🇸
Periman Eye Institute, Seattle, Washington, United States

and more 18 locations

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Phase 2

Completed

Conditions: Blepharitis

Interventions: Drug: TP-03, 0.25%
Drug: TP-03 Vehicle

First Posted Date: 2020-07-17

Last Posted Date: 2023-12-21

Lead Sponsor: Tarsus Pharmaceuticals, Inc.

Target Recruit Count: 421

Registration Number: NCT04475432

Locations: 🇺🇸
Vision Institute, Colorado Springs, Colorado, United States
🇺🇸
Alpine Research Organization, Layton, Utah, United States
🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States

and more 12 locations

Home Terms & Conditions Privacy Policy